Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Fusion Pharmaceuticals Inc.
Headquarters: Hamilton, ON, Canada
Website: N/A
Year Founded: 2014
Status: Acquired
BioCentury | Feb 4, 2025
Finance
Australian radiopharma play Advancell taps VCs for $112M in ‘scale capital’
Expanding in U.S., the biotech will build manufacturing capacity for α-emitters, including clinical program for prostate cancer
BioCentury | Dec 30, 2024
Product Development
The uncertainty principle: Hello, 2025
BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025
BioCentury | Sep 17, 2024
Finance
Why radiopharma Pentixapharm chose Frankfurt for IPO
Eckert & Ziegler spinout aiming for 4Q24 debut with secondary listing as future option
BioCentury | Jul 22, 2024
Product Development
Battle of the alphas: lead-212 picks up speed in radiopharma
The ɑ-emitting radioisotope’s rapid decay has logistical drawbacks, but its supply could beat actinium-225’s on scale
BioCentury | Jul 20, 2024
Product Development
Susan Galbraith: Five trends will drive the future of cancer treatment
Part 2 of an interview with AstraZeneca’s head of oncology
BioCentury | Jun 12, 2024
Management Tracks
Former Fusion CFO Crowley joins Centessa
Weinhoff becomes CBO. Plus: QurAlis pads C-suite and updates from PepGen, C4 and more
BioCentury | May 2, 2024
Deals
Novartis gains α-emitter, radioligand platform via $1B Mariana takeout
Largest upfront M&A payment for a preclinical biotech in three years
BioCentury | Apr 24, 2024
Product Development
Next-wave radiopharmaceuticals: insights from AACR
Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potential
BioCentury | Mar 26, 2024
Deals
Deals Report: Week’s M&A includes AZ-Fusion, Novo Nordisk-Cardior
Plus: Intellia deciding to step back from co-developing Factor-IX therapy with Regeneron and GSK returns Sosei’s GPR35 agonist after deprioritization
BioCentury | Mar 21, 2024
Data Byte
Radiopharmaceuticals could soon get their first blockbuster
Pluvicto’s steep launch appears on track to surpass $1B in sales this year
Items per page:
1 - 10 of 44